Drug intelligence / Profile preview

bispecific antibody + di-DTPA-131I

Development stage: Unknown
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

A pretargeted radioimmunotherapy approach combining a bispecific monoclonal antibody (BsmAb) targeting carcinoembryonic antigen (CEA) and DTPA-indium complex with a radioactive di-DTPA-131I hapten. The BsmAb first localizes to CEA-expressing tumor cells, and after a clearance interval (typically 4-5 days), the radioactive hapten is administered, binding to the second specificity of the BsmAb, delivering radiation specifically to the tumor site.

Beyond the preview

Go deeper on bispecific antibody + di-DTPA-131I.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bispecific antibody + di-DTPA-131I.

Explore the full profile